NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物相似藥(Adalimumab,Infliximab,Etanercept)的全球市場(2020年∼2030年):COVID-19造成的成長與變化

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change

出版商 The Business Research Company 商品編碼 975752
出版日期 按訂單生產 內容資訊 英文 200 Pages
商品交期: 2-10個工作天內
價格
生物相似藥(Adalimumab,Infliximab,Etanercept)的全球市場(2020年∼2030年):COVID-19造成的成長與變化 Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change
出版日期: 按訂單生產內容資訊: 英文 200 Pages
簡介

本報告提供全球生物相似藥(Adalimumab,Infliximab,Etanercept)市場的相關調查,提供市場規模與預測,趨勢,策略,佔有率,成長及阻礙因素,產品·用途·流通管道·各區各國的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 摘要整理

第2章 市場特性

第3章 市場規模與成長

  • 全球市場(2015-2019)
    • 市場成長要素
    • 阻礙市場要素
  • 全球市場預測(2019-2023F,2025F,2030F)

第4章 市場區隔

  • 全球市場及預測:各產品(2015-2019,2023F,2025F,2030F)
  • Adalimumab的生物相似藥(Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others))
  • Infliximab的生物相似藥(Inflectra,Renflexis,Ixifi,Avsola)
  • Cipleumab(Erelzi,Eticovo)
  • 全球市場及預測:各用途(2015-2019,2023F,2025F,2030F)
  • 克隆氏症
  • 乾癬性關節炎
  • 類風濕性關節炎
  • 潰瘍性大腸炎
  • 僵直性脊椎炎
  • 斑塊型乾癬
  • 其他
  • 全球市場及預測:各流通管道(2015-2019,2023F,2025F,2030F)
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第5章 各區各國分析

  • 全球市場及預測:各地區(2015-2019,2023F,2025F,2030F)
  • 全球市場及預測:各國(2015-2019,2023F,2025F,2030F)

第6章 亞太地區

第7章 中國

第8章 印度

第9章 日本

第10章 澳洲

第11章 印尼

第12章 韓國

第13章 西歐

第14章 英國

第15章 德國

第16章 法國

第17章 東歐

第18章 俄羅斯

第19章 北美

第20章 美國

第21章 南美

第22章 巴西

第23章 中東

第24章 非洲

第25章 競爭情形和企業簡介

  • 競爭情形
  • 企業簡介
    • Zydus Cadila
    • Sandoz (Novartis)
    • Samsung Bioepis
    • Abbvie
    • Amgen

第26章 主要合併和收購

第27章 市場趨勢與策略

第28章 市場未來展望和潛在的分析

第29章 附錄

目錄

“Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID 19 Growth And Change” from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global adalimumab, infliximab and etanercept biosimilars global market report 2020-30 market.

This report focuses on adalimumab, infliximab and etanercept biosimilars global market report 2020-30 market which is experiencing strong growth. The report gives a guide to the adalimumab, infliximab and etanercept biosimilars global market report 2020-30 market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the adalimumab, infliximab and etanercept biosimilars global market report 2020-30? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30” market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider adalimumab, infliximab and etanercept biosimilars global market report 2020-30 market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the Covid 19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The adalimumab, infliximab and etanercept biosimilars global market report 2020-30 market section of the report gives context. It compares the adalimumab, infliximab and etanercept biosimilars global market report 2020-30 market with other segments of the adalimumab, infliximab and etanercept biosimilars global market report 2020-30 market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, adalimumab, infliximab and etanercept biosimilars global market report 2020-30 indicators comparison.

Scope

Markets Covered:

  • 1) By Product: Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others); Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)
  • 2) By Application: Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Ankylosing spondylitis; Plaque psoriasis; Others
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series:: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations:: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1. Executive Summary

2. Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics

3. Adalimumab, Infliximab and Etanercept Biosimilars Market Size And Growth

  • 3.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Historic Market, 2015 - 2019, $ Billion
    • 3.1.1. Drivers Of The Market
    • 3.1.2. Restraints On The Market
  • 3.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
    • 3.2.1. Drivers Of The Market
    • 3.2.2. Restraints On the Market

4. Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

  • 4.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others)
  • Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola)
  • Cipleumab (Erelzi, Eticovo)
  • 4.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Crohn's disease
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Ulcerative colitis
  • Ankylosing spondylitis
  • Plaque psoriasis
  • Others
  • 4.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

5. Adalimumab, Infliximab and Etanercept Biosimilars Market Regional And Country Analysis

  • 5.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • 5.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 6.1. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 6.2. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 7.1. China Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 7.2. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 8.1. India Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 8.2. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 9.1. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 9.2. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 10.1. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 11.1. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 12.1. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 13.1. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 13.2. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 14.1. UK Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 14.2. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 15.1. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 16.3. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 17.1. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 17.2. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 18.1. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 19.1. North America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 19.2. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 20.1. USA Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 20.2. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 21.1. South America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 21.2. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 22.1. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 23.1. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 23.2. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 24.1. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 24.2. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape And Company Profiles

  • 25.1. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape
  • 25.2. Adalimumab, Infliximab and Etanercept Biosimilars Market Company Profiles
    • 25.2.1. Zydus Cadila
      • 25.2.1.1. Overview
      • 25.2.1.2. Products and Services
      • 25.2.1.3. Strategy
      • 25.2.1.4. Financial Performance
    • 25.2.2. Sandoz (Novartis)
      • 25.2.2.1. Overview
      • 25.2.2.2. Products and Services
      • 25.2.2.3. Strategy
      • 25.2.2.4. Financial Performance
    • 25.2.3. Samsung Bioepis
      • 25.2.3.1. Overview
      • 25.2.3.2. Products and Services
      • 25.2.3.3. Strategy
      • 25.2.3.4. Financial Performance
    • 25.2.4. Abbvie
      • 25.2.4.1. Overview
      • 25.2.4.2. Products and Services
      • 25.2.4.3. Strategy
      • 25.2.4.4. Financial Performance
    • 25.2.5. Amgen
      • 25.2.5.1. Overview
      • 25.2.5.2. Products and Services
      • 25.2.5.3. Strategy
      • 25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market

27. Adalimumab, Infliximab and Etanercept Biosimilars Market Trends And Strategies

28. Adalimumab, Infliximab and Etanercept Biosimilars Market Future Outlook and Potential Analysis

29. Appendix

  • 29.1. Abbreviations
  • 29.2. Currencies
  • 29.3. Research Inquiries
  • 29.4. The Business Research Company
  • 29.5. Copyright And Disclaimer